Affinity and selectivity of matrix metalloproteinase inhibitors: A chemometrical study from the perspective of ligands and proteins

Journal of Medicinal Chemistry

Volumn 42, Issue 22, 1999, Pages 4506-4523

  Matter, Hans ^a   Schwab, Wilfried ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; STROMELYSIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; ENZYME INHIBITION; LIGAND BINDING; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BINDING; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION;

EID: 0033524009     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990250u     Document Type: Article

References (92)

1. (a) Woessner, J. F., Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5, 2145-2154.
2. (b) Birkedal-Hansen, H.; Moore, W. G. I.; Bodden, M. K.; Windsor, L. J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J. A. Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 1993, 4, 197-250.
3. (c) Murphy, G.; Docherty, A. J. P. The matrix metalloproteinases and their inhibitors. A. J. Res. Cell. Mol. Biol. 1992, 7, 120-125.
4. (d) Matrisian, L. M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990, 6, 121-125.
5. (a) Stetler-Stevenson, W. G.; Krutsch, H. C.; Liotta, L. A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J. Biol. Chem. 1989, 264, 17374-17378.
6. (b) Docherty, A. J. P.; Lyons, A.; Smith, B. J.; Wright, E. M.; Stephens, P. E.; Harris, T. J. R.; Murphy, G.; Reynolds, J. J. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985, 318, 66-69.
7. (c) Enghild, J. J.; Salvesen, G.; Brew, K.; Nagase, H. Interaction of human rheumatoid synovial collagenase (matrix metalloproteinase 1) and stromelysin (matrix metalloproteinase 3) with human a2-macroglobulin and chicken ovostatin. Binding kinetics and identification of matrix metalloproteinase cleavage sites. J. Biol. Chem. 1989, 264, 8779-8785.
8. (a) Murphy, G. J. P.; Murphy, G.; Reynolds, J. J. The origin of matrix metalloproteinases and their familial relationships. FEBS Lett. 1991, 289, 4-7.
9. (b) Stetler-Stevenson, W. G.; Liotta, L. A.; Kleiner, D. E., Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993, 7, 1434-1441.
10. (c) Shingleton, W. D.; Hodges, D. J.; Brick, P.; Cawston, T. E. Collagenase: a key enzyme in collagen turnover. Biochem. Cell Biol. 1996, 74, 759-775.
11. (a) Murphy, G.; Hembry, R. M. Proteinases in rheumatoid arthritis. J. Rheumatol. 1992, 19, 61-64.
12. (b) Lohmander L. S.; Hoerrner L. A.; Lark M. W. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthrit. Rheum. 1993, 36, 181-189.
13. Wernicke, D.; Seyfert, C.; Hinzmann, B.; Gromnica-Ihle, E. Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. J. Rheumatol. 1996, 23, 590-595.
14. Peress, N.; Perillo, E.; Zucker, S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J. Neuropathol. Exp. Neurol. 1995, 54, 16-22.
15. (a) Nishino, N.; Powers, J. C. Design of potent reversible inhibitors for thermolysin. Peptides containing zinc coordinating ligands and their use in affinity chromatography. Biochemistry 1979, 18, 4340-4347.
16. (b) Powers, J. C.; Harper, J. W. Inhibitors of metalloproteinases. In Proteinase Inhibitors; Barrett, A. J., Salvesen, G., Eds.; Elsevier: Amsterdam, 1986; pp 219-298.
17. (c) Johnson, W. H.; Roberts, N. A.; Borkakoti, N. Collagenase inhibitors: Their design and potential therapeutic use. J. Enzyme Inhib. 1987, 2, 1-22.
18. (d) Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Inhibition of Matrix Metalloproteinases: Structure Based Design. Curr. Pharm. Design 1996, 2, 624-661.
19. (e) Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug Discuss. Today 1996, 1, 16-26.
20. (f) Beckett, R. P. Recent advances in the field of matrix metalloproteinase inhibitors. Exp. Opin. Ther. Patents 1996, 6, 193-198.
21. (g) Beckett, R. P.; Whittaker, M. Matrix metalloproteinase inhibitors 1998. Exp. Opin. Ther. Patents 1998, 8, 259-282.
22. Becker, J. W.; Marcy, A. I.; Rokosz, L. L.; Axel, M. G.; Burbaum, J. J.; Fitzgerald, P. M. D.; Cameron, P. M.; Esser, C. K.; Hagmann, W. K.; Hermes, J. D.; Springer, J. P. Stromelysin-1: Three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci. 1995, 4, 1966-1976.
23. Stams, T.; Spurlino, J. C.; Smith, D. L.; Wahl, R. C.; Ho, T. F.; Qoronfleh, M. W.; Banks, T. M.; Rubin, B. Structure of human neutrophil collagenase reveals large S1′ specificity pocket. Nature Struct. Biol. 1994, 1, 119-123.
24. Grams, F.; Reinemer, P.; Powers, J.; Kleine, T.; Pieper, M.; Tschesche, H.; Huber, R.; Bode, W. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors; implications for substrate binding and rational drug design. Eur. J. Biochem. 1995, 228, 830-841.
25. Reinemer, P.; Grams, F.; Huber, R.; Kleine, T.; Schnierer, S.; Pieper, M.; Tschesche, H.; Bode, W. Structural implications for the role of the N-terminus in the "superactivation" of collagenases. FEBS Lett. 1994, 338, 227-233.
26. Grams, F.; Crimmin, M.; Hinnes, L.; Huxley, P.; Pieper, M.; Tschesche, H.; Bode, W. Structure determination and analysis of human collagenase complexed with a hydroxamate inhibitor. Biochemistry 1995, 34, 14012-14020.
27. Matter, H.; Schwab, W.; Barbier, D.; Billen, G.; Haase, B.; Neises, B.; Schudok, M.; Thorwart, W.; Schreuder, H.; Brachvogel, V.; Lönze, P.; Weithmann, K. U.Quantitative Structure-Activity Relationship of Human Neutrophil Collagenase (MMP-8) Inhibitors Using Comparative Molecular Field Analysis and X-ray Structure Analysis. J. Med. Chem. 1999, 42, 1908-1920.
28. PDB files from Protein Database (National Brookhaven Laboratories): 1MMB, 1MNC, 1KBC, 1JAN, 1JAO, 1JAP, and 1JAQ (http://www.pdb.bnl.gov). Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 1977, 112, 535-542.
29. (a) Goodford, P. J. A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857.
30. (b) Boobbyer, D. N. A.; Goodford, P. J.; McWhinnie, P. M.; Wade, R. C. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J. Med. Chem. 1989, 32, 1083-1094.
31. (c) Wade, R. C.; Clerk, K. J.; Goodford, P. J. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 1. Ligand probe groups with the ability to form two hydrogen bonds. J. Med. Chem. 1993, 36, 140-147.
32. (d) Wade, R. C.; Goodford, P. J. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds. J. Med. Chem. 1993, 36, 148-156.
33. Goodford, P. GRID version. 16 for SGI; Molecular Discovery Ltd.: Oxford, U.K., 1996.
34. Pastor, M.; Cruciani, G. A Novel Strategy for Improving Ligand Selectivity in Receptor-Based Drug Design. J. Med. Chem. 1995, 38, 4637-4647.
35. Cruciani, G.; Goodford, P. J. A search for specificity in DNA-drug interactions. J. Mol. Graphics 1994, 12, 116-129.
36. Cramer, R. D.; Patterson, D. E.; Bunce, J. E. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
37. Clark, M.; Cramer, R. D.; Jones, D. M.; Patterson, D. E.; Simeroth, P. E. Comparative Molecular Field Analysis (CoMFA). 2. Towards its use with 3D-Structural Databases. Tetrahedron Comput. Methods 1990, 3, 47-59.
38. 3D-QSAR in Drug Design. Theory, Methods and Applications; Kubinyi, H., Ed.; ESCOM: Leiden (NL), 1993.
39. (a) Klebe, G.; Abraham, U.; Mietzner, T. Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of Drug Molecules to Correlate and Predict Their Biological Activity. J. Med. Chem. 1994, 37, 4130-4146.
40. (b) Klebe, G.; Abraham, U. Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries. J. Comput.-Aided Mol. Des. 1999, 13, 1-10.
41. (c) Böhm, M.; Stürzebecher, J.; Klebe, G. Three-Dimensional Quantitative Structure-Activity Relationship Analyses Using Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis To Elucidate Selectivity Differences of Inhibitors Binding to Trypsin, Thrombin, and Factor Xa. J. Med. Chem. 1999, 42, 458-477.
42. (d) Klebe, G. Comparative molecular similarity indices analysis. CoMSIA. Perspect. Drug Discovery Des. 1998, 12/13/14, 87-104.
43. Baroni, M.; Costantino, G.; Cruciani, G.; Riganelli, D.; Valigi, R.; Clementi, S. Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D-QSAR Problems. Quant. Struct.-Act. Relat. 1993, 12, 9-20.
44. (a) Wold, S.; Albano, C.; Dunn, W. J.; Edlund, U.; Esbenson, K.; Geladi, P.; Hellberg, S.; Lindberg, W.; Sjöström, M. In Chemometrics: Mathematics and Statistics in Chemistry; Kowalski, B., Ed.; Reidel: Dortrecht, The Netherlands, 1984; pp 17-95.
45. (b) Dunn, W. J.; Wold, S.; Edlund, U.; Hellberg, S.; Gasteiger, J. Multivariate Structure-Activity Relationship Between Data from a Battery of Biological Tests and an Ensemble of Structure Descriptors: The PLS Methodology. Quant. Struct.-Act. Relat. 1984, 3, 31-137.
46. (c) Geladi, P. Notes on the history and nature of Partial Least Squares (PLS) modelling. J. Chemom. 1988, 2, 231-246.
47. (d) Geladi, P.; Kowalski, B. R. Partial least-squares regression: a tutorial. Anal. Chem. Acta 1986, 185, 1-17.
48. (e) Jöreskog, K., Wold, H., Eds. Chemical Systems under Indirect Observation; North-Holland: Amsterdam, NL, 1982.
49. (a) Wold, S. Cross-Validatory Estimation of the Number of Component in Factor and Principal Component Models. Technometrics 1978, 4, 397-405.
50. (b) Diaconis, P.; Efron, B. Computer-Intensive Methods for Statistics. Sci. Am. 1984, 116, 96-117.
51. (c) Cramer, R. D.; Bunce, J. D.; Patterson, D. E. Crossvalidation, Bootstrapping and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies. Quant.-Struct.-Act. Relat. 1988, 7, 18-25.
52. Schlechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157-162.
53. Schwab, W.; Thorwart, W.; Barbier, D.; Billen, G.; Haase, B.; Matter, H.; Neises, B.; Schudok, M.; Weithmann, K. U. Tetrahydroisoquinolirie-3-carboxylate based Matrix Metalloproteinase Inhibitors: Design, Synthesis and Structure-Activity Relationship. Bioorg. Med. Chem., to be submitted.
54. Thorwart, W.; Schwab, W.; Schudok, M.; Haase, B.; Bartnik, E.; Weithmann, K.-Preparation of cyclic N-substituted α-iminohydroxamates as matrix metalloproteinase inhibitors. U. Ger. Offen., 17 pp. CODEN: GWXXBX. DE 19542189 A1 970515. CAN 127:50547.
55. SYBYL Molecular Modelling Package, Versions 6.4, 6.5; Tripos: St. Louis, MO, 1997/8.
56. Clark, M.; Cramer, R. D.; Van Opdenbosch, N. Validation of the general purpose Tripos 5.2 force field. J. Comput. Chem. 1989, 10, 982-1912.
57. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
58. (a) Ghose, A.; Crippen, G. Atomic Physicochemical Parameters for Three-Dimensional Structure-Directed Quantitative Structure-Activity Relationships. 1. Partition Coefficients as a Measure of Hydrophobicity. J. Comput. Chem. 1986, 7, 565-577.
59. (b) Viswanadhan, V. N.; Ghose, A. K.; Revankar, G. R.; Robins, R. K. Atomic Physicochemical Parameters for Three-Dimensional Structure-Directed Quantitative Structure-Activity Relationships. 4. Additional Parameters for Hydrophobic and Dispersive Interactions and Their Application for an Automated Superposition of Certain Naturally Occurring Nucleoside Antibiotics. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.
60. Kearsley, S. K.; Smith, G. M. An Alternative Method for the Alignment of Molecular Structures: Maximizing Electrostatic and Steric Overlap. Tetrahedron Comput. Method 1990, 3, 615-633.
61. (a) Thibaut, U.; Folkers, G.; Klebe, G.; Kubinyi, H.; Merz, A.; Rognan, D. Recommendations for CoMFA Studies and 3D QSAR Publications. In 3D QSAR in Drug Design. Theory, Methods and Applications; Kubinyi, H., Ed., ESCOM: Leiden, The Netherlands, 1993; pp 711-717.
62. (b) Folkers, G.; Merz, A.; Rognan, D. CoMFA: Scope and Limitations. Ibid. pp 583-616.
63. (c) Cramer, R. D.; DePriest, S. A.; Patterson, D. E.; Hecht, P. The Developing Practice of Comparative Molecular Field Analysis. Ibid. pp 443-485.
64. Sheridan, R. P.; Nachbar, R. B.; Bush, B. L. Extending the trend vector: The trend matrix and sample-based partial least squares. J. Comput.-Aided Mol. Design 1994, 8, 323-340.
65. Clementi, S. Golpe 3.0, SGI version; Multivariate Infometrics Analyses (MIA): Perugia, Italy, 1995.
66. Cruciani, G.; Watson, K. A. Comparative Molecular Field Analysis Using GRID Force-Field and GOLPE Variable Selection Methods in a Study of Inhibitors of Glycogen Phosphorylase b. J. Med. Chem. 1994, 37, 2589-2601.
67. Nilsson, J.; Wikström, H.; Smilde, A.; Glase, S.; Pugsley, T.; Cruciani, G.; Pastor, M.; Clementi, S. GRID/GOLPE 3D Quantitative Structure-Activity Relationship Study on a Set of Benzamides and Naphthamides, with Affinity for the Dopamine D3 Receptor Subtype. J. Med. Chem. 1997, 40, 833-840.
68. (a) Mitchell, T. J. An Algorithm for the Construction of "D-optimal" Experimental Designs. Technometrics 1974, 16, 203-210.
69. (b) Steinberg, D. M.; Hunter, W. G. Experimental Design Review and Comment. Technometrics 1984, 26, 71-76.
70. Morgan, E. In Chemometrics: Experimental Design; Chadwick, N., Ed.; John Wiley and Sons Ltd.: Chichester, U.K., 1991.
71. Cruciani, G.; Baroni, M.; Costantino, G.; Riganelli, D.; Skagerberg, B. Predictive Ability of Regression Models. Part 1: Standard Deviation of Prediction Errors (SDEP). J. Chemom. 1992, 6, 335-346.
72. (a) Pastor, M.; Cruciani, G.; Clementi, S. Smart Region Definition: A New Way to Improve the Predictive Ability and Interpretability of Three-Dimensional Quantitative Structure-Activity Relationships. J. Med. Chem. 1997, 40, 1455-1464.
73. (b) Clementi, S.; Cruciani, G.; Riganelli, D.; Valigi, R. GOLPE: Mertis and Drawbacks in 3D-QSAR. In QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications; Sanz, F., Giraldo, J., Manaut, F., Eds.; Prous Science Publ.: Barcelona, 1996; pp 408-414.
74. 2-Guided Region Selection for Comparative Molecular Field Analysis: A Simple Method to Achieve Consistent Results. J. Med. Chem. 1995, 38, 1060-1066.
75. (b) Norinder, U. Single and Domain Mode Variable Selection in 3D QSAR Applications. J. Chemometr. 1996, 10, 95-105.
76. (a) Dillon, W. R.; Goldstein, M. Multivariate Analysis: Methods and Applications; Wiley: New York, 1984.
77. (b) Malinowski, E. R.; Howery, D. G. Factor Analysis in Chemistry; Wiley: New York, 1980.
78. (c) Cramer, R. D. BC(DEF) Parameters. 1. The Intrinsic Dimensionality of Intermolecular Interactions in the Liquid State. J. Am. Chem. Soc. 1980, 102, 1837-1849.
79. (d) Stahle, L.; Wold, S. Multivariate Data Analysis and Experimental Design in Biomedical Research. in Progress in Medicinal Chemistry; Ellis, G. P., West, G. B., Eds.; Elsevier: Amsterdam, 1988; pp 292-338.
80. (e) Wold, S.; Albano, C.; Dunn, W. J., III; Edlund, U.; Esbensen, K.; Geladi, P.; Hellberg, S.; Johanson, E.; Lindberg, W.; Sjöström, M. Multivariate Data Analysis in Chemistry. In Chemometrics: Mathematics and Statistics in Chemistry; Kowalski, B. R., Ed.; NATO, ISI Series C 138; D. Reidel Publ. Co.: Dordrecht, Holland, 1984; pp 17-96.
81. 50 × 100 000).
82. Clark, M.; Cramer, R. D. The Probability of Chance Correlation using Partial Least Squares (PLS). Quant. Struct.-Act. Relat. 1993, 12, 137-145.
83. Betz, M.; Huxley, P.; Davies, S. J.; Mushtaq, Y.; Pieper, M.; Tschesche, H.; Bode, W.; Gomis-Rüth, F. X. 1.8 Å crystal structure of the catalytic domain of human neutrophil collagenase (mtarix metalloprotemase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur. J. Biochem. 1997, 247, 356-363.
84. Wong, G.; Koehler, K. F.; Skolnick, P.; Gu, Z.; Ananthan, S.; Schönholzer, P.; Hunkeler, W.; Zhang, W.; Cook, J. M. Synthetic and Computer-Assisted Analysis of the Structural Requirements for Selective, High Affinity Ligand Binding to Diazepam-Insensitive Benzodiazepine Receptors. J. Med. Chem. 1993, 36, 1820-1830.
85. 50) of an enzymatic reaction. Biochem. Pharm. 1973, 22, 3099-3108.
86. (a) ReliBase Version 3.2. Febr. 24. 1999 (8959 PDB complexes) from M. Hendlich, University Marburg, Germany: http:// www2.ebi.ac.uk: 8081/home.html.
87. (b) Hendlich, M.; Rippmann, F.; Barnickel, G.; Hemm, K.; Aberer, K. RELIBase - an object-oriented comprehensive receptor-ligand database. Folding Des. 1996, 1, 30.
88. (c) Hendlich, Manfred. Databases for protein-ligand complexes. Acta Crystallogr. 1998, D54, 1178-1182.
89. Fitzpatrick, P. A.; Steinmetz, A. C. U.; Ringe, D.; Klibanov, A. M. Enzyme crystal structure in a neat organic solvent. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8653-8657.
90. Guddat, L. W.; Shan, L.; Anchin, J. M.; Linthicum, D. S.; Edmundson, A. B. Local and transmitted conformational changes on complexation of an anti-sweetener Fab. J. Mol. Biol. 1994, 236, 247-274.
91. (a) Skulnick, H. I.; Johnson, P. A.; Aristoff, P. A.; Morris, J. K.; Lovasz, K. D.; Howe, W. J.; Watenpaugh, K. D.; Janakiraman, M. N.; Anderson, D. J.; Reischer, R. J.; Schwartz, T. M.; Banitt, L. S.; Tomich, P. K.; Lynn, J. C.; Horng, M.; Chong, K.; Hinshaw, R. R.; Dolak, L. A.; Seest, E. P.; Schwende, F. J.; Rush, B. D.; Howard, G. M.; Toth, L. N.; Wilkinson, K. R.; Kakuk, T. J.; Johnson, C. W.; Cole, S. L.; Zaya, R. M.; Zipp, G. L.; Possert, P. L.; Dalga, R. J.; Zhong, W.; Williams, M. G.; Romines, K. R. Structure-Based Design of Nonpeptidic HIV Protease Inhibitors: The Sulfonamide-Substituted Cyclooctylpyranones. J. Med. Chem. 1997, 40, 1149-1164.
92. (b) Skulnick, H. I.; Johnson, P. D.; Howe, W. J.; Tomich, P. K.; Chong, K.; Watenpaugh, K. D.; Janakiraman, M. N.; Dolak, L. A.; McGrath, J. P. Structure-Based Design of Sulfonamide-Substituted Non-Peptidic HIV Protease Inhibitors. J. Med. Chem. 1995, 38, 4968-4971.